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To the Editor:
Blastic NK cell lymphomas are rare hematopoietic malig-
nancies characterized by a frequent skin involvement, an
evolution toward leukemia, and a rapid aggressive course
with bone marrow infiltration. In contrast to myeloid/NK cell
acute leukemia, CD4þCD56þ malignancies usually lack
the expression of conventional myeloid and lymphoid T and
B cell markers (Bagot et al, 1998; Petrella et al, 1999;
Chaperot et al, 2001). Several recent studies reported
phenotypic and functional similarities between these
CD4þCD56þ leukemic cells and a subtype of dendritic
cells (DC), the so-called plasmacytoid DC or type 2 den-
dritic cells (DC2) (Petrella et al, 1999; Chaperot et al, 2001).
Tumor cells and DC2 both express CD4 and CD56 antigens
(Cella et al, 1999; Chaperot et al, 2001). When stimulated by
IL-3 or CD40 ligand, DC2 and CD4þCD56þ tumor cells
both differentiated into mature DC and promote T-helper
response (Chaperot et al, 2001). DC2 seems to be special-
ized in human anti-viral immunity producing high amounts
of type I interferon (IFN-a and b) upon viral infection (Cella
et al, 1999). Similarly, CD4þCD56þ blastic cells produce
IFN-a in response to virus (Chaperot et al, 2001). CD101 is a
human leukocyte cell surface molecule, initially defined by
two different monoclonal antibodies (MoAb): BA27 and
BB27 (Boumsell et al, 1997). In normal individuals, it is ex-
pressed by a minor subset of circulating T lymphocytes, by
intestinal mucosal T lymphocytes, and by a major DC sub-
set including DC2 (Petrella et al, 2002). CD101 antigen plays
a major role in the activation of T lymphocytes by DC (Bagot
et al, 1997). Although some reported that CD101 ligation on
T cells inhibits IL-2 production by activated T cells (Soares
et al, 1998), others indicated an inhibition of the T cell pro-
liferation via IL-10 secretion by cutaneous DC (Bouloc et al,
2000). Here, we focused on the expression of CD101 mol-
ecules on CD4þCD56þ blastic cells.
The study was conducted according to the Declaration
of Helsinki Principles. After informed consent and approval
by an ethics committee of the Paris XII University, the iden-
tification of CD101 expression was carried out in 17 patients
with CD4þCD56þ malignancy by immunohistochemistry
using the anti-CD101 MoAb BC27 previously described by
Boumsell et al (1997). We used the streptavidin/biotin alka-
line phosphatase method previously described on frozen
cutaneous section (Bouloc et al, 2000) as BC27 MoAb did
not give significant staining on paraffin-embedded section.
Next, flow cytometry analysis was performed, using a PC5-
conjugated anti-CD4 MoAb (Coulter Immunotech, Marseille,
France), a PE-conjugated anti-CD56 MoAb (Coulter
Immuno;tech), or the anti-CD101/BC27 MoAb produced
locally (Inserm U448, Cre´teil, France), on the peripheral
Figure1
Expression of CD101 by the CD4þCD56þ tumor lymphocytes. (a)
Cryostat tumor section, immunostaining with the CD101 antibody. (b)
Immunofluorescence analysis of circulating lymphocytes: cells were
stained either with anti-CD101 monoclonal antibodies (MoAb) followed
by FITC-conjugated isotype-specific goat anti-mouse second reagent,
PC5-conjugated anti-CD4 MoAb or with PE-conjugated anti-CD56
MoAb. Shaded histogram corresponds to unrelevant IgG1 MoAb con-
trol staining. Stained cells were analyzed using a single argon flow
cytometer analyzer (Epics XL, Beckman-Coulter, Miami, Florida).
Abbreviations: DC, dendritic cells; DC2, type 2 dendritic cells; IFN,
interferon; MoAb, monoclonal antibodies; PBMC, peripheral blood
mononuclear cells
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blood mononuclear cells (PBMC) in one of the patients with
tumor blood involvement.
In 13 patients (76%), CD101-stained cells with blastic
morphology were present in the cutaneous infiltrate
(Fig 1a). No correlation was found with the evolution, the
localization, or the dissemination of the disease. In the
analyzed blood sample, 90% of PBMC, corresponding to
circulating tumor cells, expressed CD101, CD4, and
CD56 antigens. The profile of CD101 antibody binding
to CD4þCD56þ cells corresponded to a weak homoge-
neous expression by the malignant cell population
(Fig 1b). It should be noted that three-color flow cytometry
analysis was performed and revealed that as expected cir-
culating cells coexpressed CD4, CD56, and CD101 mole-
cules (data not shown). We show that CD4þCD56þ tumor
cells co-express the CD101 marker. It further supports
the identity between DC2 and CD4þCD56þ tumor cells.
Moreover, CD101 could represent a useful tool for the di-
agnosis of the CD4þCD56þ blastic tumors. In the near
future it will be important to determine the role of CD101 in
the pathogenesis of this tumor, as it is tempting to speculate
that CD101 could promote the progression of the disease
by inducing a tumor-specific tolerance by inhibiting reactive
T cell proliferation via IL-10 secretion (Bouloc et al, 2000).
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